Tags

Type your tag names separated by a space and hit enter

The therapeutic potential of cannabinoids for movement disorders.
Mov Disord. 2015 Mar; 30(3):313-27.MD

Abstract

There is growing interest in the therapeutic potential of marijuana (cannabis) and cannabinoid-based chemicals within the medical community and, particularly, for neurological conditions. This interest is driven both by changes in the legal status of cannabis in many areas and increasing research into the roles of endocannabinoids within the central nervous system and their potential as symptomatic and/or neuroprotective therapies. We review basic science as well as preclinical and clinical studies on the therapeutic potential of cannabinoids specifically as it relates to movement disorders. The pharmacology of cannabis is complex, with over 60 neuroactive chemicals identified to date. The endocannabinoid system modulates neurotransmission involved in motor function, particularly within the basal ganglia. Preclinical research in animal models of several movement disorders have shown variable evidence for symptomatic benefits, but more consistently suggest potential neuroprotective effects in several animal models of Parkinson's (PD) and Huntington's disease (HD). Clinical observations and clinical trials of cannabinoid-based therapies suggests a possible benefit of cannabinoids for tics and probably no benefit for tremor in multiple sclerosis or dyskinesias or motor symptoms in PD. Data are insufficient to draw conclusions regarding HD, dystonia, or ataxia and nonexistent for myoclonus or RLS. Despite the widespread publicity about the medical benefits of cannabinoids, further preclinical and clinical research is needed to better characterize the pharmacological, physiological, and therapeutic effects of this class of drugs in movement disorders.

Authors+Show Affiliations

Movement Disorders Center, Department of Neurology, University of Colorado School of Medicine, Aurora, Colorado, USA.No affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't
Review

Language

eng

PubMed ID

25649017

Citation

Kluger, Benzi, et al. "The Therapeutic Potential of Cannabinoids for Movement Disorders." Movement Disorders : Official Journal of the Movement Disorder Society, vol. 30, no. 3, 2015, pp. 313-27.
Kluger B, Triolo P, Jones W, et al. The therapeutic potential of cannabinoids for movement disorders. Mov Disord. 2015;30(3):313-27.
Kluger, B., Triolo, P., Jones, W., & Jankovic, J. (2015). The therapeutic potential of cannabinoids for movement disorders. Movement Disorders : Official Journal of the Movement Disorder Society, 30(3), 313-27. https://doi.org/10.1002/mds.26142
Kluger B, et al. The Therapeutic Potential of Cannabinoids for Movement Disorders. Mov Disord. 2015;30(3):313-27. PubMed PMID: 25649017.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The therapeutic potential of cannabinoids for movement disorders. AU - Kluger,Benzi, AU - Triolo,Piera, AU - Jones,Wallace, AU - Jankovic,Joseph, Y1 - 2015/02/04/ PY - 2014/08/19/received PY - 2014/11/10/revised PY - 2014/12/01/accepted PY - 2015/2/5/entrez PY - 2015/2/5/pubmed PY - 2015/12/15/medline KW - Huntington's disease KW - Parkinson's disease KW - cannabinoids KW - cannabis KW - movement disorders SP - 313 EP - 27 JF - Movement disorders : official journal of the Movement Disorder Society JO - Mov Disord VL - 30 IS - 3 N2 - There is growing interest in the therapeutic potential of marijuana (cannabis) and cannabinoid-based chemicals within the medical community and, particularly, for neurological conditions. This interest is driven both by changes in the legal status of cannabis in many areas and increasing research into the roles of endocannabinoids within the central nervous system and their potential as symptomatic and/or neuroprotective therapies. We review basic science as well as preclinical and clinical studies on the therapeutic potential of cannabinoids specifically as it relates to movement disorders. The pharmacology of cannabis is complex, with over 60 neuroactive chemicals identified to date. The endocannabinoid system modulates neurotransmission involved in motor function, particularly within the basal ganglia. Preclinical research in animal models of several movement disorders have shown variable evidence for symptomatic benefits, but more consistently suggest potential neuroprotective effects in several animal models of Parkinson's (PD) and Huntington's disease (HD). Clinical observations and clinical trials of cannabinoid-based therapies suggests a possible benefit of cannabinoids for tics and probably no benefit for tremor in multiple sclerosis or dyskinesias or motor symptoms in PD. Data are insufficient to draw conclusions regarding HD, dystonia, or ataxia and nonexistent for myoclonus or RLS. Despite the widespread publicity about the medical benefits of cannabinoids, further preclinical and clinical research is needed to better characterize the pharmacological, physiological, and therapeutic effects of this class of drugs in movement disorders. SN - 1531-8257 UR - https://www.unboundmedicine.com/medline/citation/25649017/The_therapeutic_potential_of_cannabinoids_for_movement_disorders_ L2 - https://doi.org/10.1002/mds.26142 DB - PRIME DP - Unbound Medicine ER -